Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931245 | 0.86 | GRM5 (0.51) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL1477377 | 0.74 | GRM5 (0.49) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL8486570 | 0.74 | GRM5 (0.47) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL9948053 | 0.73 | GRM5 (0.47) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL1477046 | 0.71 | GRM5 (0.55) | GRM5HTT | |
| SCHEMBL5742874 | 0.69 | GRM5 (0.38) | GRM5CYP2A6 | |
| SCHEMBL19567095 | 0.69 | GRM5 (0.44) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL3722709 | 0.69 | GRM5 (0.48) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL3802122 | 0.69 | GRM5 (0.44) | GRM5CYP2A6POLBHCAR2HTT | |
| SCHEMBL3665917 | 0.69 | CYP2A6 (0.54) | GRM5CYP2A6HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | GRM5 2512/4885CYP2A6 3946/4885POLB 129/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | GRM5 2512/4885CYP2A6 3946/4885POLB 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.